Top

Published in:

01-02-2019 | Original Article

Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly

Authors: Wagner A. Poles, Erika E. Nishi, Mariana B. de Oliveira, Angela I. P. Eugênio, Tathiana A. de Andrade, Antonio Hugo F. M. Campos, Ruy R. de Campos Jr., José Vassallo, Antonio C. Alves, Cristovam Scapulatempo Neto, Roberto Antonio Pinto Paes, Gilles Landman, Maria Cláudia N. Zerbini, Gisele W. B. Colleoni

Published in: Cancer Immunology, Immunotherapy | Issue 2/2019

Abstract

Aging immune deterioration and Epstein–Barr (EBV) intrinsic mechanisms play an essential role in EBV-positive diffuse large B-cell lymphoma (DLBCL) of the elderly (EBV + DLBCLe) pathogenesis, through the expression of viral proteins, interaction with host molecules and epigenetic regulation, such as miR-155, required for induction of M1 phenotype of macrophages. This study aims to evaluate the relationship between macrophage polarization pattern in the tumor microenvironment and relative expression of miR-155 in EBV + DLBCLe and EBV-negative DLBCL patients. We studied 28 EBV + DLBCLe and 65 EBV-negative DLBCL patients. Tumor-associated macrophages (TAM) were evaluated by expression of CD68, CD163 and CD163/CD68 ratio (degree of M2 polarization), using tissue microarray. RNA was extracted from paraffin-embedded tumor samples for miR-155 relative expression study. We found a significantly higher CD163/CD68 ratio in EBV + DLBCLe compared to EBV-negative DLBCL. In EBV-negative DLBCL, CD163/CD68 ratio was higher among advanced-staged/high-tumor burden disease and overexpression of miR-155 was associated with decreased polarization to the M2 phenotype of macrophages. The opposite was observed in EBV + DLBCLe patients: we found a positive association between miR-155 relative expression and CD163/CD68 ratio, which was not significant after outlier exclusion. We believe that the higher CD163/CD68 ratio in this group is probably due to the presence of the EBV since it directly affects macrophage polarization towards M2 phenotype through cytokine secretion in the tumor microenvironment. Therapeutic strategies modulating miR-155 expression or preventing immuno-regulatory and pro-tumor macrophage polarization could be adjuvants in EBV + DLBCLe therapy since this entity has a rich infiltration of M2 macrophages in its tumor microenvironment.

Available only for authorised users

Swerdlow SH, World Health Organization (2008) Who Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4. edn, World Health Organization Classification of Tumours. Lyon: International Agency for Research on Cancer (IARC)

Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y et al (2003) Senile EBV + B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27(1):16–26CrossRefPubMed

Nikolich-Zugich J (2008) Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol 8(7):512–22. https://doi.org/10.1038/nri2318 CrossRefPubMedPubMedCentral

Castillo JJ, Beltran BE, Miranda RN, Paydas S, Winer ES, Butera JN (2011) Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 16(1):87–96. https://doi.org/10.1634/theoncologist.2010-0213 CrossRefPubMedPubMedCentral

Nakamura S, Jaffe ES, Swerdlow SH (2008) EBV positive diffuse large B-cell lymphoma of the elderly. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. 4th Lyon: International Agency for Research on Cancer (IARC), pp 243–244

Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosia SG, Mazorra F et al (2012) EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 25(7):968–982. https://doi.org/10.1038/modpathol.2012.52 CrossRefPubMed

Ok CY, Papathomas TG, Medeiros LJ, Young KH (2013) EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 122:328–340CrossRefPubMedPubMedCentral

Andrade TA, Evangelista AF, Campos AH, Poles WA, Borges NM, Camillo CM et al (2014) A microRNA signature profile in EBV + diffuse large B-cell lymphoma of the elderly. Oncotarget 5(23):11813–11826. https://doi.org/10.18632/oncotarget.2952 CrossRefPubMedPubMedCentral

Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B et al (2013) A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood 122(2):243–252. https://doi.org/10.1182/blood-2012-08-449306 CrossRefPubMed

10.

Nam SJ, Go H, Paik JH, Kim TM, Heo DS, Kim CW et al (2014) An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 55(11):2466–2476. https://doi.org/10.3109/10428194.2013.879713 CrossRefPubMed

11.

De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M et al (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211–226. https://doi.org/10.1016/j.ccr.2005.08.002 CrossRefPubMed

12.

Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51. https://doi.org/10.1016/j.cell.2010.03.014 CrossRefPubMedPubMedCentral

13.

Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G (2013) Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One 8(11):e80908. https://doi.org/10.1371/journal.pone.0080908 CrossRefPubMedPubMedCentral

14.

Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J et al (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70(14):5728–5739. https://doi.org/10.1158/0008-5472.CAN-09-4672 CrossRefPubMed

15.

Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M (2009) Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 59 (5):300–5. https://doi.org/10.1111/j.1440-1827.2009.02369.x CrossRefPubMed

16.

Hasan D, Chalouhi N, Jabbour P, Hashimoto T (2012) Macrophage imbalance (M1 vs. M2) and upregulation of mast cells in wall of ruptured human cerebral aneurysms: preliminary results. J Neuroinflamm 9:222. https://doi.org/10.1186/1742-2094-9-222 CrossRef

17.

Gomez-Gelvez JC, Salama ME, Perkins SL, Leavitt M, Inamdar KV (2016) Prognostic impact of tumor microenvironment in diffuse large B-cell lymphoma uniformly treated with R-CHOP chemotherapy. Am J Clin Pathol 145(4):514–523. https://doi.org/10.1093/ajcp/aqw034 CrossRefPubMed

18.

Wang J, Gao K, Lei W, Dong L, Xuan Q, Feng M et al (2017) Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget 8(3):5414–5425. https://doi.org/10.18632/oncotarget.14289 CrossRefPubMed

19.

Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T et al (2013) Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat 12 (3):259–267. https://doi.org/10.7785/tcrt.2012.500312 CrossRefPubMed

20.

Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y et al (2013) Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 108(4):914–923. https://doi.org/10.1038/bjc.2013.32 CrossRefPubMedPubMedCentral

21.

Weber M, Buttner-Herold M, Hyckel P, Moebius P, Distel L, Ries J et al (2014) Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages–an immunohistochemical analysis. J Craniomaxillofac Surg 42(7):1087–1094. https://doi.org/10.1016/j.jcms.2014.01.035 CrossRefPubMed

22.

International Non-Hodgkin’s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994. https://doi.org/10.1056/NEJM199309303291402 CrossRef

23.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262 CrossRefPubMed

24.

Goni R, García P, Foissac S (2012) The qPCR data statistical analysis. Integromics W P 9:1–9

25.

Hinkle DE, Wiersma W, Jurs SG (2003) Applied statistics for the behavioral sciences, 5th edn. Houghton Mifflin, Boston

26.

Sandhu SK, Croce CM, Garzon R (2011) Micro-RNA expression and function in lymphomas. Adv Hematol 2011:347137. https://doi.org/10.1155/2011/347137 CrossRefPubMedPubMedCentral

27.

Lawrie CH (2013) MicroRNAs and lymphomagenesis: a functional review. Br J Haematol 160(5):571–581. https://doi.org/10.1111/bjh.12157 CrossRefPubMed

28.

Wada M, Okamura T, Okada M, Teramura M, Masuda M, Motoji T et al (1999) Frequent chromosome arm 13q deletion in aggressive non-Hodgkin’s lymphoma. Leukemia 13(5):792–798CrossRefPubMed

29.

Li C, Kim SW, Rai D, Bolla AR, Adhvaryu S, Kinney MC et al (2009) Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 113(26):6681–6690. https://doi.org/10.1182/blood-2009-01-202028 CrossRefPubMedPubMedCentral

30.

Wong KY, Yim RL, Kwong YL, Leung CY, Hui PK, Cheung F et al (2013) Epigenetic inactivation of the MIR129-2 in hematological malignancies. J Hematol Oncol 6:16. https://doi.org/10.1186/1756-8722-6-16 CrossRefPubMedPubMedCentral

31.

Robertus JL, Kluiver J, Weggemans C, Harms G, Reijmers RM, Swart Y et al (2010) MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol 149(6):896–899. https://doi.org/10.1111/j.1365-2141.2010.08111.x CrossRefPubMed

32.

Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J et al (2004) Identification of virus-encoded microRNAs. Science 304(5671):734–736. https://doi.org/10.1126/science.1096781 CrossRefPubMed

33.

Barth S, Meister G, Grasser FA (2011) EBV-encoded miRNAs. Biochim Biophys Acta 1809(11–12):631–640. https://doi.org/10.1016/j.bbagrm.2011.05.010 CrossRefPubMed

34.

Morscio J, Finalet Ferreiro J, Vander Borght S, Bittoun E, Gheysens O, Dierickx D et al (2017) Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma. Mod Pathol 30(3):370–381. https://doi.org/10.1038/modpathol.2016.199 CrossRefPubMed

35.

Sato A, Yamakawa N, Okuyama K, Kotani A, Nakamura N, Ando K (2014) The critical interaction between Epstein-Barr virus (EBV) positive B-cells and tumor associated macrophages (TAMs). Blood 124:2989

36.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. https://doi.org/10.1038/nature07205 CrossRefPubMed

37.

Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC et al (2007) The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110(3):972–978. https://doi.org/10.1182/blood-2007-01-067769

38.

Riihijarvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O et al (2015) Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica 100(2):238–245. https://doi.org/10.3324/haematol.2014.113472 CrossRefPubMedPubMedCentral

39.

Marinaccio C, Ingravallo G, Gaudio F, Perrone T, Nico B, Maoirano E et al (2014) Microvascular density, CD68 and tryptase expression in human diffuse large B-cell lymphoma. Leuk Res 38(11):1374–1377. https://doi.org/10.1016/j.leukres.2014.09.007 CrossRefPubMed

40.

Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R et al (2011) The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 135(1):54–61. https://doi.org/10.1309/AJCPJX4BJV9NLQHY CrossRefPubMed

41.

Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson PO (2008) Expression of CD68 + tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 58(8):529–532. https://doi.org/10.1111/j.1440-1827.02268.x CrossRefPubMed

42.

Coutinho R, Clear AJ, Mazzola E, Owen A, Greaves P, Wilson A et al (2015) Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica 100(3):363–369. https://doi.org/10.3324/haematol.2014.110189 CrossRefPubMedPubMedCentral

43.

Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E et al (2015) High density of CD68+/CD163 + tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 33(2):110–112. https://doi.org/10.1002/hon.2142 CrossRefPubMed

44.

Wada N, Zaki MA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y et al (2012) Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 60(2):313–319. https://doi.org/10.1111/j.1365-2559.2011.04096.x CrossRefPubMed

45.

Jeong J, Oh EJ, Yang WI, Kim SJ, Yoon SO (2017) Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma. Hum Pathol 64:222–231. https://doi.org/10.1016/j.humpath.2017.04.012 CrossRefPubMed

46.

O’Connell RM, Chaudhuri AA, Rao DS, Baltimore D (2009) Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 106(17):7113–7118. https://doi.org/10.1073/pnas.0902636106 CrossRefPubMedPubMedCentral

47.

Baran CP, Tridandapani S, Helgason CD, Humphries RK, Krystal G, Marsh CB (2003) The inositol 5′-phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. J Biol Chem 278(40):38628–38636. https://doi.org/10.1074/jbc.M305021200 CrossRefPubMed

48.

Mondal S, Subramanian KK, Sakai J, Bajrami B, Luo HR (2012) Phosphoinositide lipid phosphatase SHIP1 and PTEN coordinate to regulate cell migration and adhesion. Mol Biol Cell 23(7):1219–1230. https://doi.org/10.1091/mbc.E11-10-0889 CrossRefPubMedPubMedCentral

49.

Rajaram MV, Butchar JP, Parsa KV, Cremer TJ, Amer A, Schlesinger LS et al (2009) Akt and SHIP modulate Francisella escape from the phagosome and induction of the Fas-mediated death pathway. PLoS One 4(11):e7919. https://doi.org/10.1371/journal.pone.0007919 CrossRefPubMedPubMedCentral

50.

Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG et al (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18(5):349–355. https://doi.org/10.1016/j.semcancer.2008.03.004 CrossRefPubMed

51.

Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22(2):231–237. https://doi.org/10.1016/j.coi.2010.01.009 CrossRefPubMed

52.

Tan G, Visser L, Tan L, Berg A, Diepstra A (2018) The microenvironment in Epstein–Barr virus-associated malignancies. Pathogens 7:2. https://doi.org/10.3390/pathogens7020040 CrossRef

53.

Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR (2010) Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 84(22):11670–11678. https://doi.org/10.1128/JVI.01248-10 CrossRefPubMedPubMedCentral

54.

Yin Q, McBride J, Fewell C, Lacey M, Wang X, Lin Z et al (2008) MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J Virol 82(11):5295–5306. https://doi.org/10.1128/JVI.02380-07 CrossRefPubMedPubMedCentral

55.

Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M (2008) Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res 36(20):6608–6619. https://doi.org/10.1093/nar/gkn666 CrossRefPubMedPubMedCentral

56.

Essandoh K, Li Y, Huo J, Fan GC (2016) MiRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response. Shock 46(2):122–131. https://doi.org/10.1097/SHK.0000000000000604 CrossRefPubMedPubMedCentral

57.

Lu L, McCurdy S, Huang S, Zhu X, Peplowska K, Tiirikainen M et al (2016) Time series miRNA-mRNA integrated analysis reveals critical miRNAs and targets in macrophage polarization. Sci Rep 6:37446. https://doi.org/10.1038/srep37446 CrossRefPubMedPubMedCentral

58.

Zhang P, Wang H, Luo X, Liu H, Lu B, Li T et al (2018) MicroRNA-155 inhibits polarization of macrophages to M2-type and suppresses choroidal neovascularization. Inflammation 41(1):143–153. https://doi.org/10.1007/s10753-017-0672-8 CrossRefPubMed

59.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569 CrossRefPubMedPubMedCentral

60.

Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9:177. https://doi.org/10.1186/1479-5876-9-177 CrossRefPubMedPubMedCentral

61.

Miselis NR, Wu ZJ, Van Rooijen N, Kane AB (2008) Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7(4):788–799. https://doi.org/10.1158/1535-7163.MCT-07-0579 CrossRefPubMed

62.

Clinical Trials NCT02637531 (2017) https://clinicaltrials.gov/ct2/show/NCT02637531>. Accessed 18 Jul 2017

63.

Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S et al (2016) PI3Kgamma is a molecular switch that controls immune suppression. Nature 539(7629):437–442. https://doi.org/10.1038/nature19834 CrossRefPubMedPubMedCentral

64.

De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH et al (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539(7629):443–447. https://doi.org/10.1038/nature20554 CrossRefPubMedPubMedCentral

Title: Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly
Authors: Wagner A. Poles
Erika E. Nishi
Mariana B. de Oliveira
Angela I. P. Eugênio
Tathiana A. de Andrade
Antonio Hugo F. M. Campos
Ruy R. de Campos Jr.
José Vassallo
Antonio C. Alves
Cristovam Scapulatempo Neto
Roberto Antonio Pinto Paes
Gilles Landman
Maria Cláudia N. Zerbini
Gisele W. B. Colleoni
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 2/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2273-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis

The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design

Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer

Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer